极光激酶A：靶点失效了？

Aurora A: target invalidated?

作者信息

Cochran Andrea G

机构信息

Department of Protein Engineering, Genentech Inc, South San Francisco, CA 94080, USA.

出版信息

Chem Biol. 2008 Jun;15(6):525-6. doi: 10.1016/j.chembiol.2008.06.002.

DOI:10.1016/j.chembiol.2008.06.002

PMID:18559262

Abstract

Aurora kinases are important mitotic regulators, and Aurora kinase inhibitors are under investigation as treatments for cancer. An ongoing debate in the field is which Aurora kinase is the better drug target. A new study (Girdler et al., 2008, in this issue of Chemistry & Biology) pushes the case forward for Aurora B.

摘要

极光激酶是重要的有丝分裂调节因子，极光激酶抑制剂正作为癌症治疗药物进行研究。该领域目前存在的一个争论是哪种极光激酶是更好的药物靶点。一项新的研究（Girdler等人，2008年，本期《化学生物学》）为支持极光B激酶提供了新的依据。